This post was originally published on this site

[unable to retrieve full-text content]Sanofi SNY announced that a pivotal phase III study evaluating its blockbuster inflammatory drug Dupixent (dupilumab) to treat uncontrolled moderate-to-severe asthma in children aged from six to 11 …